Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BH3120 |
Synonyms | |
Therapy Description |
BH3120 is a bispecific antibody targeting CD274 (PD-L1) and TNFRSF9 (4-1BB), which potentially induces antitumor immune activity (Cancer Res (2023) 83 (7_Supplement): 1799). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BH3120 | BH-3120|BH 3120 | PD-L1/PD-1 antibody 122 TNFRSF9 Antibody 32 | BH3120 is a bispecific antibody targeting CD274 (PD-L1) and TNFRSF9 (4-1BB), which potentially induces antitumor immune activity (Cancer Res (2023) 83 (7_Supplement): 1799). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06234397 | Phase I | BH3120 | Dose Escalation and Expansion Study of BH3120 in Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |